Although Aduhelm, a monoclonal antibody targeting amyloid beta (Aβ), recently became the first US FDA approved drug for Alzheimer’s disease (AD) based on its ability to decrease Aβ plaque burden in AD patients, its effect on cognitive improvement is still controversial. Moreover, about 40% of the patients treated with this antibody experienced serious side effects including cerebral edemas (ARIA-E) and hemorrhages (ARIA-H) that are likely related to inflammatory responses in the brain when the Aβ antibody binds Fc receptors (FCR) of immune cells such as microglia and macrophages. These inflammatory side effects can cause neuronal cell death and synapse elimination by activated microglia, and even have the potential to exacerbate cognitive impairment in AD patients. Thus, current Aβ antibody-based immunotherapy holds the inherent risk of doing more harm than good due to their inflammatory side effects.
You may also be interested in:
Researchers have successfully engineered human immune cells to model an infection common among immunocompromised people in a discovery that paves the way for new drug [...]
All children born before full term are more likely to have poorer attainment during primary school compared with children born full term (39–41 weeks), but [...]
A new study published in the Journal of Eating Disorders found that, in course of a year, over half of men, women, and transgender or [...]